Study on Torvutatug Samrotecan and Bevacizumab for First-line Maintenance in Advanced Ovarian Cancer Without HRD
Sponsor: AstraZeneca
ClinicalTrials ID:NCT07851025
This clinical trial is testing whether a combination of the drugs Torvutatug Samrotecan and Bevacizumab can help patients with advanced ovarian cancer live longer without their cancer worsening, compared to using Bevacizumab alone.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to find out if using Torvutatug Samrotecan together with Bevacizumab can help patients with advanced ovarian cancer live longer without their cancer getting worse, compared to using Bevacizumab by itself. This study is for patients whose cancer has not progressed after initial treatment with chemotherapy and Bevacizumab. Patients must test negative for HRD and have a specific folate receptor status confirmed by a test.
Description
This study is focused on patients with advanced ovarian cancer who have completed their first round of chemotherapy and Bevacizumab treatment without their cancer getting worse. The study will compare the effects of adding Torvutatug Samrotecan to Bevacizumab against using Bevacizumab alone. The goal is to see if the combination treatment can help patients live longer without their cancer progressing. To participate, patients must have a specific type of ovarian cancer and meet certain health criteria, including testing negative for HRD and having a confirmed folate receptor status.
Eligibility Criteria
Inclusion Criteria
- Newly diagnosed with advanced high-grade ovarian, fallopian tube, or primary peritoneal cancer.
- Must provide a previous tumor sample for analysis.
- Completed 6 to 8 cycles of initial chemotherapy before joining the study.
- Received at least 3 cycles of Bevacizumab with the last 3 cycles of chemotherapy.
- Completed surgery to remove as much of the cancer as possible, or have cancer that cannot be surgically removed.
- Cancer has not worsened after initial treatment.
- Tested negative for HRD.
Exclusion Criteria
- Have a type of tumor that is not epithelial, or have borderline or low-grade tumors.
- Have a history of lung conditions that required treatment with steroids or oxygen, or have current lung issues that cannot be ruled out.
- Have a wound, ulcer, or bone fracture that is not healing.
- Have an active or ongoing bowel blockage.
- Have previously received any treatment targeting the folate receptor or certain antibody-drug treatments.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Research Site | 33606 | Tampa | Florida |
| Research Site | 21201 | Baltimore | Maryland |
| Research Site | 59106 | Billings | Montana |
| Research Site | 44195 | Cleveland | Ohio |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.